hyperhomocysteinemia

From Aaushi
Jump to navigation Jump to search

Etiology

* homozygous state results in homocystinuria

# cofactor in parenthesis

Epidemiology

Pathology

Laboratory

* see screening for hyperhomocysteinemia

Management

More general terms

Additional terms

References

  1. Stein JH and McBride PE Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Int Med 158:1301 1998 PMID: https://www.ncbi.nlm.nih.gov/pubmed/9645823
  2. Jump up to: 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 2199
  4. Jump up to: 4.0 4.1 Journal Watch 22(1):2, 2002 Brown BG et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11757504
  5. Jump up to: 5.0 5.1 Journal Watch 22(7):56-57, 2002 Seshadri S et al Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346:476, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11844848
  6. Jump up to: 6.0 6.1 Journal Watch 22(24):181, 2002 Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387654
    Klerk M et al MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387655
    Wilson PW Homocysteine and coronary heart disease: how great is the hazard? JAMA 288:2042, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387658
  7. Jump up to: 7.0 7.1 Journal Watch 24(12):94, 2004 a) van Meurs JB et al Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004 May 13;350(20):2033-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141041
    McLean RR et al Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004 May 13;350(20):2042-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141042
    Raisz LG Homocysteine and osteoporotic fractures--culprit or bystander? N Engl J Med. 2004 May 13;350(20):2089-90. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141048
  8. Jump up to: 8.0 8.1 Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004 Jun 24;350(26):2673-81. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15215483
  9. Jump up to: 9.0 9.1 Prescriber's Letter 12(9): 2005 High-dose B vitamins and Heart disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=211108&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. Jump up to: 10.0 10.1 Sato Y, Iwamoto J, Kanoko T, Satoh K Homocysteine as a predictive factor for hip fractures in elderly women with Parkinson's disease American Journal of Medicine 118:1250, 2005
  11. Jump up to: 11.0 11.1 McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006 Jun 29;354(26):2764-72. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16807413
  12. Jump up to: 12.0 12.1 Durga J et al, Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007 Jan 20;369(9557):208-16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17240287
  13. Jump up to: 13.0 13.1 Ray JG et al, Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Intern Med 2007, 246:761 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17470822
  14. Jump up to: 14.0 14.1 Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007 Sep 12;298(10):1163-70. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17848650
    Baigent C, Clarke R. B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. JAMA. 2007 Sep 12;298(10):1212-4. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17848657
  15. Jump up to: 15.0 15.1 15.2 Albert CM et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008 May 7; 299:2027 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18460663
  16. Jump up to: 16.0 16.1 House AA et al Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy JAMA. 2010;303(16):1603-1609. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20424250 <Internet> http://jama.ama-assn.org/cgi/content/full/303/16/1603
  17. Jardine MJ et al The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis BMJ 2012;344:e3533 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22695899 <Internet> http://www.bmj.com/content/344/bmj.e3533
    Haynes R and Clarke R Homocysteine, the kidney, and vascular disease BMJ 2012;344:e3925 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22695904 <Internet> http://www.bmj.com/content/344/bmj.e3925
  18. Ray JG. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med. 2008 Sep;14(5):369-73 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18664964
  19. Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007 Apr;44(2):70-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17433898

Database